Differential diagnosis and management of abnormal uterine bleeding due to hyperprolactinemia

American College of O, Gynecologists, 2013, ACOG committee opinion no. 557: Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women, Obstet Gynecol, 121, 891, 10.1097/01.AOG.0000428646.67925.9a Sweet, 2012, Evaluation and management of abnormal uterine bleeding in premenopausal women, Am Fam Physician, 85, 35 Fazio, 2007, Abnormal uterine bleeding, South Med J, 100, 376, 10.1097/SMJ.0b013e31802f35f2 Best, 2006, Abnormal uterine bleeding: etiology, evaluation and end-points for the non- gynecologist, Northeast Florida Med, 57, 27 Liu, 2007, A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding, Value Health, 10, 183, 10.1111/j.1524-4733.2007.00168.x Dubois, 2006, The effect of abnormal uterine bleeding on health-related quality of life, Obstet Gynecol, 107, 23S, 10.1097/00006250-200604001-00052 Singh, 2013, Abnormal uterine bleeding in pre-menopausal women, J Obstet Gynaecol Can, 35, S1, 10.1016/S1701-2163(15)30732-5 Munro, 2011, Disorders FWGoM. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age, Int J Gynaecol Obstet, 113, 3, 10.1016/j.ijgo.2010.11.011 Lee, 2012, Prevalence of hyperprolactinemia in adolescents and young women with menstruationrelated problems, Am J Obstet Gynecol, 206, 213, 10.1016/j.ajog.2011.12.010 Eftekhari, 2008, The prevalence of hyperprolactinemia and galactorrhea in patients with abnormal uterine bleeding, Gynecol Endocrinol, 24, 289, 10.1080/09513590701672355 Melmed, 2011, Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 96, 273, 10.1210/jc.2010-1692 Hansen, 2006, Hyperprolactinemia and the dopamine receptor, US Endocrine Disease, 74, 10.17925/USE.2006.00.1.74 Exton, 2001, Coitus-induced orgasm stimulates prolactin secretion in healthy subjects, Psychoneuroendocrinology, 26, 287, 10.1016/S0306-4530(00)00053-6 Kruger, 2012, Prolactin secretory rhythm in women: immediate and long-term alterations after sexual contact, Hum Reprod, 27, 1139, 10.1093/humrep/des003 La Torre, 2007, Pharmacological causes of hyperprolactinemia, Ther Clin Risk Manage, 3, 929 Molitch, 2005, Medication-induced hyperprolactinemia, Mayo Clin Proc, 80, 1050, 10.4065/80.8.1050 Iglesias, 2013, Macroprolactinoma: a diagnostic and therapeutic update, QJM, 106, 495, 10.1093/qjmed/hcs240 Gillam, 2006, Advances in the treatment of prolactinomas, Endocr Rev, 27, 485, 10.1210/er.2005-9998 Lee, 2012, Prevalence of hyperprolactinemia in adolescents and young women with menstruation-related problems, Am J Obstet Gynecol, 206, 10.1016/j.ajog.2011.12.010 Majumdar, 2013, Hyperprolactinemia, J Hum Reprod Sci, 6, 168, 10.4103/0974-1208.121400 Martin, 1985, The natural history of idiopathic hyperprolactinemia, J Clin Endocrinol Metab, 60, 855, 10.1210/jcem-60-5-855 Skugor M, Hamrahian AH. Pituitary Disorders. Published: June 2012. Available at: <http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/endocrinology/pituitary-disorders/> [accessed on 28/04/5]. Oner G. Prolactin and Infertility. Published: January 2013. In: György M. Nagy, editor, ISBN: 978-953-51-0943-3, InTech, http://dx.doi.org/10.5772/55557. Available from: http://www.intechopen.com/books/prolactin/prolactin-and-infertility [accessed on 18/05/2015]. Schüring, 2016, Establishing reference intervals for sex hormones on the analytical platforms advia centaur and immulite 2000XP, Ann Lab Med, 36, 55, 10.3343/alm.2016.36.1.55 Beltran, 2008, Serum total prolactin and monomeric prolactin reference intervals determined by precipitation with polyethylene glycol: evaluation and validation on common immunoassay platforms, Clin Chem, 54, 1673, 10.1373/clinchem.2008.105312 Seidl, 2000, MRI–diagnostic and follow-up tool for microprolactinomas, Funct Neurol, 15, 47 Chaudhary, 2011, Imaging of the pituitary: recent advances, Ind J Endocrinol Metab, 15 Di Sarno, 2003, An evaluation of patients with hyperprolactinemia: have dynamic tests had their day?, J Endocrinol Invest, 26, 39 Marcovitz, 1988, Diagnostic accuracy of preoperative CT scanning of pituitary prolactinomas, AJNR Am J Neuroradiol, 9, 13 Pereira, 2011, Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia, Curr Opin Endocrinol Diabetes Obes, 18, 264, 10.1097/MED.0b013e328347c94a Colao, 1997, Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage, J Clin Endocrinol Metab, 82, 3574, 10.1210/jcem.82.11.4368 Verhelst, 1999, Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients, J Clin Endocrinol Metab, 84, 2518, 10.1210/jcem.84.7.5810 dos Santos Nunes, 2011, Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and metaanalysis, Pituitary, 14, 259, 10.1007/s11102-010-0290-z Buyukbayrak, 2010, Effectiveness of shortterm maintenance treatment with cabergoline in microadenomarelated and idiopathic hyperprolactinemia, Arch Gynecol Obstet, 282, 561, 10.1007/s00404-010-1562-6 Dekkers, 2010, Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis, J Clin Endocrinol Metab, 95, 43, 10.1210/jc.2009-1238 Glezer, 2014, Prolactinoma, Arq Bras Endocrinol Metabol, 58, 118, 10.1590/0004-2730000002961 Cesar de Oliveira Naliato, 2008, Quality of life in women with microprolactinoma treated with dopamine agonists, Pituitary, 11, 247, 10.1007/s11102-008-0091-9 Weiss, 1983, Natural history of microprolactinomas: six-year follow-up, Neurosurgery, 12, 180, 10.1227/00006123-198302000-00008 Bolanowski, 2015, Pituitary disorders and osteoporosis, Int J Endocrinol, 2015, 206853, 10.1155/2015/206853 Colao, 2011, Medical treatment of prolactinomas, Nat Rev Endocrinol, 7, 267, 10.1038/nrendo.2011.37 Kars, 2010, Update in prolactinomas, Neth J Med, 68, 104 Oki, 2014, Medical management of functioning pituitary adenoma: an update, Neurol Med Chir (Tokyo), 54, 958, 10.2176/nmc.ra.2014-0239 Colao, 2006, Drug insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women, Nat Clin Pract Endocrinol Metab, 2, 200, 10.1038/ncpendmet0160 Glezer, 2015, Prolactinomas, Endocrinol Metab Clin North Am, 44, 71, 10.1016/j.ecl.2014.11.003 Colao, 2002, Dopamine receptor agonists for treating prolactinomas, Exp Opin Invest Drugs, 11, 787, 10.1517/13543784.11.6.787 Verhelst, 2003, Hyperprolactinemia: pathophysiology and management, Treat Endocrinol, 2, 23, 10.2165/00024677-200302010-00003 Colao, 2000, Cabergoline, Exp Opin Pharmacother, 1, 555, 10.1517/14656566.1.3.555 Colao, 2000, Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients, J Clin Endocrinol Metab, 85, 2247 Krysiak, 2015, Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels, Basic Clin Pharmacol Toxicol, 116, 251, 10.1111/bcpt.12307 Casanueva, 2006, Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas, Clin Endocrinol (Oxf), 65, 265, 10.1111/j.1365-2265.2006.02562.x Vilar, 2015, Second attempt of cabergoline withdrawal in patients with prolactinomas after a failed first attempt: is it worthwhile?, Front Endocrinol (Lausanne), 6, 11, 10.3389/fendo.2015.00011 Colao, 2003, Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia, N Engl J Med, 349, 2023, 10.1056/NEJMoa022657 Sowiński, 2013, Pharmacoeconomic aspects of the treatment of pituitary gland tumours, Contemp Oncol (Pozn), 17, 137 Colao, 1997, Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment, J Clin Endocrinol Metab, 82, 876, 10.1210/jcem.82.3.3822 Bajwa, 2011, Management of prolactinoma with cabergoline treatment in a pregnant woman during her entire pregnancy, Ind J Endocrinol Metab, 15 Anderson, 1999, Neurology of the pituitary gland, J Neurol Neurosurg Psychiatry, 66, 703, 10.1136/jnnp.66.6.703 Crosignani, 2012, Management of hyperprolactinemic infertility, Middle East Fertil Soc J, 17, 63, 10.1016/j.mefs.2012.04.003 Motazedian, 2010, A comparison of bromocriptine & cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination, Ind J Med Res, 131, 670 Ferrari, 1992, Cabergoline in the longterm therapy of hyperprolactinemic disorders, Acta Endocrinol (Copenh), 126, 489, 10.1530/acta.0.1260489 Kasum, 2014, Importance of macroprolactinemia in hyperprolactinemia, Eur J Obstet Gynecol Reprod Biol, 183, 28, 10.1016/j.ejogrb.2014.10.013 Strachan, 2003, Clinical and radiological features of patients with macroprolactinaemia, Clin Endocrinol (Oxf), 59, 339, 10.1046/j.1365-2265.2003.01852.x Richa, 2010, Macroprolactin; a frequent cause of misdiagnosed hyperprolactinemia in clinical practice, J Reprod Infertil, 11, 161 Donadio, 2007, Patients with macroprolactinaemia: clinical and radiological features, Eur J Clin Invest, 37, 552, 10.1111/j.1365-2362.2007.01823.x